Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Unternehmen & Branche
| Name | Xencor Inc |
|---|---|
| Ticker | XNCR |
| CIK | 0001326732 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 98401f105 |
|---|---|
| ISIN | US98401F1057 |
| Typ | Common Stock |
| Marktkapitalisierung | 940,9 Mio. USD |
| Beta | 0,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 125,576,000 | -91,923,000 | -1.24 | 875,495,000 | 635,587,000 |
| 2025-09-30 | 10-Q | 20,999,000 | -6,027,000 | -0.08 | 868,811,000 | 625,316,000 |
| 2025-06-30 | 10-Q | 43,608,000 | -30,825,000 | -0.41 | 879,424,000 | 620,351,000 |
| 2025-03-31 | 10-Q | 32,732,000 | -48,418,000 | -0.66 | 904,689,000 | 639,874,000 |
| 2024-12-31 | 10-K | 110,493,000 | -232,618,000 | -3.58 | 951,945,000 | 677,611,000 |
| 2024-09-30 | 10-Q | 17,796,000 | -46,288,000 | -0.72 | 983,635,000 | 723,836,000 |
| 2024-06-30 | 10-Q | 23,907,000 | -67,337,000 | -1.09 | 826,167,000 | 564,325,000 |
| 2024-03-31 | 10-Q | 15,997,000 | -73,440,000 | -1.20 | 884,255,000 | 612,526,000 |
| 2023-12-31 | 10-K | 174,615,000 | -133,133,000 | -2.20 | 965,135,000 | 661,750,000 |
| 2023-09-30 | 10-Q | 59,164,000 | -24,269,000 | -0.40 | 778,430,000 | 669,010,000 |
| 2023-06-30 | 10-Q | 45,523,000 | -21,954,000 | -0.37 | 778,121,000 | 678,876,000 |
| 2023-03-31 | 10-Q | 18,962,000 | -60,763,000 | -1.02 | 803,411,000 | 683,583,000 |
| 2022-12-31 | 10-K | 164,579,000 | -55,181,000 | -0.93 | 846,266,000 | 727,496,000 |
| 2022-09-30 | 10-Q | 27,299,000 | -32,759,000 | -0.55 | 835,269,000 | 722,698,000 |
| 2022-06-30 | 10-Q | 30,175,000 | -33,975,000 | -0.57 | 851,325,000 | 742,341,000 |
| 2022-03-31 | 10-Q | 85,495,000 | 23,594,000 | 0.39 | 857,922,000 | 763,023,000 |
| 2021-12-31 | 10-K | 275,111,000 | 82,631,000 | 1.37 | 838,211,000 | 733,504,000 |
| 2021-09-30 | 10-Q | 19,683,000 | -40,191,000 | -0.69 | 697,264,000 | 618,860,000 |
| 2021-06-30 | 10-Q | 67,447,000 | 52,248,000 | 0.87 | 695,602,000 | 646,938,000 |
| 2021-03-31 | 10-Q | 33,965,000 | -2,487,000 | -0.04 | 692,737,000 | 583,612,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 11,927,218 | 0 | 11,927,218 | 182,605,708 | Neu | +100,0% | |
| PRIMECAP MANAGEMENT CO/CA/ | 10,218,322 | 0 | 10,218,322 | 156,442,509 | Neu | +100,0% | |
| VANGUARD GROUP INC | 7,165,450 | 0 | 7,165,450 | 109,703,040 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 6,777,461 | 0 | 6,777,461 | 103,762,928 | Neu | +100,0% | |
| STATE STREET CORP | 4,507,254 | 0 | 4,507,254 | 69,006,059 | Neu | +100,0% | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,500,342 | 0 | 3,500,342 | 42,214,125 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,101,647 | 0 | 3,101,647 | 37,405,863 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1,752,918 | 0 | 1,752,918 | 26,842,201 | Neu | +100,0% | |
| MORGAN STANLEY | 1,508,727 | 0 | 1,508,727 | 23,098,626 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 1,102,106 | 0 | 1,102,106 | 16,873,243 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 1,294,887 | 1,249,288 | 45,599 | 15,612,575 | Aufgestockt | +3,6% | |
| UBS Group AG | 1,082,419 | 638,021 | 444,398 | 13,053,973 | Aufgestockt | +69,7% | |
| Legal & General Group Plc | 1,066,780 | 1,308,088 | -241,308 | 12,865,366 | Reduziert | -18,4% | |
| GOLDMAN SACHS GROUP INC | 753,258 | 0 | 753,258 | 11,532,380 | Neu | +100,0% | |
| JOHNSON & JOHNSON | 748,062 | 0 | 748,062 | 11,452,829 | Neu | +100,0% | |
| Jefferies Financial Group Inc. | 720,440 | 0 | 720,440 | 11,029,936 | Neu | +100,0% | |
| Lynx1 Capital Management LP | 705,558 | 0 | 705,558 | 10,802,093 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 700,435 | 0 | 700,435 | 10,723,660 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 674,657 | 0 | 674,657 | 10,328,998 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 629,408 | 0 | 629,408 | 9,636,237 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 594,435 | 0 | 594,435 | 9,100,800 | Neu | +100,0% | |
| PANAGORA ASSET MANAGEMENT INC | 583,778 | 0 | 583,778 | 8,937,641 | Neu | +100,0% | |
| TORONTO DOMINION BANK | 491,000 | 0 | 491,000 | 7,517,210 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 425,000 | 0 | 425,000 | 6,506,750 | Neu | +100,0% | |
| VANGUARD FIDUCIARY TRUST CO | 471,076 | 0 | 471,076 | 5,681,177 | Neu | +100,0% | |
| BARCLAYS PLC | 359,235 | 0 | 359,235 | 5,499,890 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 321,808 | 0 | 321,808 | 4,926,881 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 303,979 | 0 | 303,979 | 4,653,918 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 347,078 | 340,326 | 6,752 | 4,185,761 | Aufgestockt | +2,0% | |
| TWO SIGMA INVESTMENTS, LP | 268,737 | 0 | 268,737 | 4,114,363 | Neu | +100,0% | |
| Invesco Ltd. | 265,820 | 0 | 265,820 | 4,069,705 | Neu | +100,0% | |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 259,319 | 0 | 259,319 | 3,970,174 | Neu | +100,0% | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | 247,242 | 0 | 247,242 | 3,785,275 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 216,568 | 0 | 216,568 | 3,315,656 | Neu | +100,0% | |
| Susquehanna Portfolio Strategies, LLC | 191,463 | 0 | 191,463 | 2,931,299 | Neu | +100,0% | |
| Trexquant Investment LP | 175,152 | 0 | 175,152 | 2,681,577 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 174,603 | 0 | 174,603 | 2,673,172 | Neu | +100,0% | |
| RHUMBLINE ADVISERS | 165,797 | 0 | 165,797 | 2,538,330 | Neu | +100,0% | |
| Nantahala Capital Management, LLC | 164,639 | 0 | 164,639 | 2,520,623 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 135,806 | 0 | 135,806 | 2,079,190 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 119,789 | 0 | 119,789 | 1,833,969 | Neu | +100,0% | |
| CITIGROUP INC | 112,275 | 0 | 112,275 | 1,718,930 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 112,271 | 0 | 112,271 | 1,718,869 | Neu | +100,0% | |
| Nuveen, LLC | 134,778 | 134,051 | 727 | 1,625,423 | Aufgestockt | +0,5% | |
| Essex LLC | 98,661 | 0 | 98,661 | 1,510,500 | Neu | +100,0% | |
| FMR LLC | 92,883 | 0 | 92,883 | 1,422,047 | Neu | +100,0% | |
| WINTON GROUP Ltd | 88,038 | 0 | 88,038 | 1,347,862 | Neu | +100,0% | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 87,717 | 0 | 87,717 | 1,342,947 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 82,942 | 0 | 82,942 | 1,252,541 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 79,667 | 0 | 79,667 | 1,219,702 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Cornelissen Bart Jan | Officer, SR. VICE PRESIDENT & CFO | Open Market Sale | -3,499 | 12.29 | -42,990.46 | -19,1% | |
| 2026-03-06 | Desjarlais John R | Officer, SR. VICE PRESIDENT & CSO | Open Market Sale | -2,502 | 11.02 | -27,571.29 | -12,2% | |
| 2026-03-06 | Dahiyat Bassil I | Director, Officer, PRESIDENT & CEO | Open Market Sale | -6,606 | 11.02 | -72,796.14 | -32,3% | |
| 2026-03-06 | Eckert Celia | Officer, SVP, GENERAL COUNSEL | Open Market Sale | -1,767 | 11.02 | -19,471.81 | -8,6% | |
| 2026-03-05 | Desjarlais John R | Officer, SR. VICE PRESIDENT & CSO | Open Market Sale | -4,118 | 11.25 | -46,308.97 | -20,5% | |
| 2026-03-05 | Eckert Celia | Officer, SVP, GENERAL COUNSEL | Open Market Sale | -3,244 | 11.25 | -36,480.40 | -16,2% | |
| 2026-03-05 | Dahiyat Bassil I | Director, Officer, PRESIDENT & CEO | Open Market Sale | -14,870 | 11.25 | -167,220.59 | -74,2% | |
| 2026-03-05 | Cornelissen Bart Jan | Officer, SR. VICE PRESIDENT & CFO | Open Market Sale | -2,517 | 11.25 | -28,304.92 | -12,6% | |
| 2026-03-03 | Desjarlais John R | Officer, SR. VICE PRESIDENT & CSO | Open Market Sale | -2,663 | 11.90 | -31,676.65 | -14,1% | |
| 2026-03-03 | Eckert Celia | Officer, SVP, GENERAL COUNSEL | Open Market Sale | -1,492 | 11.90 | -17,747.49 | -7,9% | |
| 2026-03-03 | Dahiyat Bassil I | Director, Officer, PRESIDENT & CEO | Open Market Sale | -6,758 | 11.90 | -80,387.09 | -35,7% | |
| 2025-12-19 | Desjarlais John R | Officer, SR. VICE PRESIDENT & CSO | Open Market Sale | -73,367 | 15.72 | -1,153,329.24 | -511,8% | |
| 2025-12-19 | Dahiyat Bassil I | Director, Officer, PRESIDENT & CEO | Open Market Sale | -114,377 | 15.71 | -1,796,862.67 | -797,4% | |
| 2025-06-16 | GORMAN KEVIN CHARLES | Director | Open Market Sale | -3,173 | 9.22 | -29,255.06 | -13,0% | |
| 2025-06-16 | GUSTAFSON KURT A | Director | Open Market Sale | -2,993 | 9.22 | -27,595.46 | -12,2% | |
| 2025-06-16 | Feigal Ellen | Director | Open Market Sale | -2,993 | 9.22 | -27,595.46 | -12,2% |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,500,342 | 42,214,125 | 29.95 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,101,647 | 37,405,863 | 26.54 |
| DIMENSIONAL FUND ADVISORS LP | 1,294,887 | 15,612,575 | 11.08 |
| UBS Group AG | 1,082,419 | 13,053,973 | 9.26 |
| Legal & General Group Plc | 1,066,780 | 12,865,366 | 9.13 |
| VANGUARD FIDUCIARY TRUST CO | 471,076 | 5,681,177 | 4.03 |
| PRINCIPAL FINANCIAL GROUP INC | 347,078 | 4,185,761 | 2.97 |
| Nuveen, LLC | 134,778 | 1,625,423 | 1.15 |
| Swiss National Bank | 98,800 | 1,191,528 | 0.85 |
| Russell Investments Group, Ltd. | 82,534 | 995,371 | 0.71 |
| HSBC HOLDINGS PLC | 58,579 | 717,007 | 0.51 |
| INTECH INVESTMENT MANAGEMENT LLC | 58,767 | 708,730 | 0.50 |
| Inspire Investing, LLC | 42,529 | 512,898 | 0.36 |
| Linden Thomas Advisory Services, LLC | 42,084 | 507,533 | 0.36 |
| Louisiana State Employees Retirement System | 31,700 | 382,302 | 0.27 |
| VANGUARD ASSET MANAGEMENT, Ltd | 31,393 | 378,600 | 0.27 |
| Vanguard Global Advisers, LLC | 27,626 | 333,170 | 0.24 |
| Diversified Trust Co | 21,528 | 259,627 | 0.18 |
| Police & Firemen's Retirement System of New Jersey | 17,627 | 212,582 | 0.15 |
| YOUSIF CAPITAL MANAGEMENT, LLC | 17,276 | 208,349 | 0.15 |